NCT00345293View on ClinicalTrials.gov

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2013

Study Completion Date

March 31, 2015

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

autologous dendritic cell vaccine (DC/PC3)

ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity

Trial Locations (1)

10065

Rockefeller University Hospital, New York

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Rockefeller University

OTHER

NCT00345293 - Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer | Biotech Hunter | Biotech Hunter